header logo image


Page 34«..1020..33343536..4050..»

Archive for the ‘Arthritis’ Category

Arthritis Drug Being Tried on Italian Coronavirus Patients – The St. Kitts-Nevis Observer

Thursday, March 19th, 2020

The situation in Italy is dire when it comes to COVID-19 currently with more than 1,000 deaths. Authorities and science are doing the impossible to make progress in combating this virus. Tocilizumab is a drug that treats moderate to severe rheumatoid arthritis. It can also treat polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA).

Now its being tried on COVID-19 and with some encouraging results.

A Chinese -Italian Team in Napes, Italy has been experimenting with this drug to fight Covid-19. This news was spread in the Italian press and from the sources of Italian secure communications: RAI-TV

A collaboration between the Colli Hospital, the Cancer Institute of Naples and Chinese doctors, it was verified that Tocilizumab can give positive results in the care of people infected with Coronavirus.

Two patients from Naples immediately responded

The drug was administered to two patients hospitalized at Cotugno Hospital (in Naples), suffering from severe Covid-19 pneumonia last Saturday. 24 hours after the infusion, encouraging improvements were highlighted, especially in one of the two patients, who arrived at the hospital as a particularly critical case. This was reported by the Neapolitan hospital of the Hills.

The same drug has been used in China in 21 patients and now for the first time has been administered in Italy in Coronavirus patience.Based on this experiment it is currently evaluated if treating other critically ill patients is recommended.

The International team

The result was made possible thanks to a great team effort mentioning: the Oncology of the Azienda dei Colli by Vincenzo Montesarchio, the Oncological Immunotherapy and Innovative Therapies of Pascale by Paolo Ascierto together with the virologist Franco Buonaguro, and some Chinese doctors, including Wei Haiming Ming from the First Affiliated Hospital of University of Science and Technology of China as well as the team of doctors from Cotugno, composed among others by Rodolfo Punzi, director of the department of infectious diseases and infectious diseases, Roberto Parrella, director of Uoc Diseases respiratory infectives, Fiorentino Fragranza, director of the Uoc Anesthesia resuscitation and intensive care, Vincenzo Sangiovanni, director of the Uoc Systemic infections and immunosuppressed, Nicola Maturo, head of the Infectivology First Aid always by Cotugno and Luigi Atripaldi, director of the Microbiology laboratory and virology.

The Chinese experience

Paolo Ascierto and Vincenzo Montesarchio explained out how 21 patients had been treated. All of them showed a visible improvement already in the first 24-48 hours after treatment. Treatment included a single solution It acted without interfering with the protocol therapeutic use based on antiviral drugs.

The downside:

According to Gunther Franke, a pharmacist in Cologne, Germany this news may be good also for Roche Pharma, the manufacturer of the medicine. 4 injections sell for 1900,00, 12 injections for 5800,00

More here:
Arthritis Drug Being Tried on Italian Coronavirus Patients - The St. Kitts-Nevis Observer

Read More...

Existing drugs may have a key role to play in coronavirus treatment – inews

Thursday, March 19th, 2020

NewsHealthLeading scientists believe 'hyperinflammation' drugs could help with worst cases of the virus

Sunday, 15th March 2020, 6:50 pm

Existing drugs for rheumatoid arthritis and cases of excessive inflammation could be used to treat some of the most severe cases of coronavirus, leading scientists say.

A recent study into coronavirus deaths in China suggested that many of the fatalities were caused by an overactive immune response in the body that was triggered by the virus - rather than by the virus itself.

This suggests that existing drugs designed to suppress these kind of overreactions in the immune system - known as 'hyperinflammation' or cytokine storms - have the potential to significantly reduce casualties from Covid-19.

However, clinical trials are needed to confirm whether these drugs are an effective coronavirus treatment, according to a panel of scientists and clinicians researching the issue.

Screen worst-hit patient

The researchers recommend that all patients who are suffering badly from coronavirus be screened for hyperinflammation with a blood test - and given steroids or other approved drugs if they are found to have it.

Deaths from Covid-19 are rising and there is an urgent need for effective treatment. We recommend identification and treatment of hyperinflammation using existing, approved therapies with proven safety profiles to address the immediate need to reduce the rising mortality, Puja Mehta, of University College London, told i.

Improving awareness of the risk of hyperinflammation and treating patients with immunosuppression therapies is likely to be important in the pandemic, she said.

"Deaths from Covid-19 are rising and there is an urgent need for effective treatment,"

Puja Mehta

Dr Mehta was speaking on behalf of a collaboration of five hyperinflammation experts from universities and hospitals across the UK. They have written an article for The Lancet journal, seen by i, outlining their case.

Immunosuppressants such as the rheumatoid arthritis treatment Actemra, anti-inflammatory 'cortico' steroids and intravenous immunoglobulin blood treatments are used to dampen the immune response and save lives.

Study of Chinese cases

A recent study into 150 cases of Covid-19 cases in China found a link between fatal cases of coronavirus and cytokine storms.

It is recognised that some patients with severe Covid-19 may have hyperinflammation which can be picked up by blood tests.

Where hyperinflammation is shown this is associated with severe coronavirus symptoms and may predict death, Dr Mehta said.

During a cytokine storm, an excessive immune response ravages healthy lung tissue, leading to acute respiratory distress and multi-organ failure. Untreated, cytokine storm syndrome is usually fatal.

Trial of arthritis treatment

Chinese authorities have approved the use of the Actemra rheumatoid arthritis treatment for lung damage arising from coronavirus.

Meanwhile, Chinese researchers have started a trial to assess the safety and effectiveness of using the drug in coronavirus patients with cytokine release syndrome.

Here is the original post:
Existing drugs may have a key role to play in coronavirus treatment - inews

Read More...

Profiles in Creating Possible: Julie Di Paolo is on a Mission to Understand Rheumatoid Arthritis and Other Inflammatory Diseases Press Releases on -…

Thursday, March 19th, 2020

Stories @ Gilead

When Julie Di Paolos father was diagnosed with Crohns disease, an inflammatory condition with limited treatment options, it sparked curiosity and drive that have carried forward into her career at Gilead, where she is Executive Director of Inflammation Biology.

I realized how few medications were being developed to treat the drivers of inflammatory diseases, and how far away the field was from delivering curative therapy, she recalls. That still sticks with me today.

Julie joined Gilead in 2010, as the company was further expanding its work outside of antivirals. While there have been moderate advances in disease understanding and treatment options, significant unmet needs remain for people living with inflammatory conditions. An estimated 38 million people around the world live with inflammatory diseases and two-thirds of patients do not achieve the current treatment goal of disease remission. According to Julie, progress is being made but much more is still needed.

Rheumatoid arthritis is an example of an inflammatory disease where a lot of the underlying pathways arent well understood, Julie explains. When someone is diagnosed, its not clear whether a particular therapy is going to work for that person. Its essentially a process of elimination until the physician and patient find the right option. Really pairing the right therapy with the right individual is the aspirational place that we want to go. We want to get a much deeper response, and bring relief to more people.

Julie and her team research a broad range of inflammatory diseases, with particular focus on studying small molecules that have the potential to inhibit the Janus kinase (JAK) family of four proteins, some of which are highly active in inflammation. Inhibiting these proteins, particularly JAK-1, has the potential to reduce inflammation, associated symptoms and disease progression.

While there is still much work to be done to fully understand the complex pathways that contribute to inflammatory diseases, Julie says headway is being made.

It starts with incrementally making progress toward understanding a disease and seeing how you can chip away at getting better responses to treatment, Julie says. The ultimate goal is to eventually get to a place where the disease is so well-maintained that it no longer impacts a persons quality of life.

Julie and her team are approaching inflammation from all sides, in what she calls an ABC treatment paradigm. The objective is toArrestthe disease, or stop it where it is and prevent it from getting worse. From there, the next step is toBalancethe condition by creating a tolerogenic environment and reducing the source of inflammation. Eventually, the team believes it will be necessary toCombinetreatments to achieve long-term control of many inflammatory diseases.

Recent progress has enabled Gilead to submit an investigational JAK-1 inhibitor for regulatory review in the United States, Europe and Japan. Addressing the existing gaps in the current standards of care also require partnerships, says Julie, pointing to Gileads 10-year global research and development collaboration with Galapagos. Scientists from the two companies are working together closely to discover and develop potential new therapies.

In science, its all about finding the truth, Julie says. These types of partnerships help create new possibilities for people living with inflammatory diseases. They allow us to bring all of the best ideas together and work collaboratively to advance those that make the most sense.

Originally posted here:
Profiles in Creating Possible: Julie Di Paolo is on a Mission to Understand Rheumatoid Arthritis and Other Inflammatory Diseases Press Releases on -...

Read More...

Combating arthritis: How to deal with this crippling disease – Free Press Journal

Thursday, March 19th, 2020

X-rays are generally a good guide to whats wrong with your hip, however it may be difficult to get complete assessment of X-rays especially in early disease, where the changes in the bony architecture may not be easily visible. Magnetic Resonance Imaging (MRI scans) are a great tool to assess the disease process and formulate plan of treatment.

Treatment plan

Once the complete assessment is done, the treatment plan is outlined based on the problems faced and the amount of pain and disability the patient has due to arthritis.

In early disease, the treatment starts with changes in the lifestyle and anti inflammatory medicines. Patient should avoid sitting on the floor and squatting. They are motivated to maintain their muscle strength and hydrotherapy and swimming are a good way to maintain movement and stamina without further damaging the already diseased joint.

A good physiotherapy protocol is formed to give them better quality of life in future. In cases of proven Rheumatoid Arthritis and Ankylosing Spondylitis, a Rheumatology specialist opinion is helpful to give them course of Disease Modifying Medicines. They help in control of the arthritis and delay the surgery to a certain extent.

When there is damage to the blood supply, medicines to reduce the blood coagulation may be effective. The aim of the non operative management is to maintain the hip strength and flexibility, and even after taking all the precautions, the disease may progress gradually to a level where a surgical intervention is needed.

When the arthritis gets worse, the patient may have to undergo some surgical intervention to be able to mobilise and lead pain free life. Although difference types of surgeries are available, you may have to head to total knee replacement in severe disease.

The results of the procedure are very predictive and patients lead nearly normal and productive life after undergoing the surgery. They get pain free range and mobility and good quality of life after surgery.

The prosthesis and bearing surfaces have also evolved over decades and the invent of Ceramic and Oxynium heads have given us hope for increased survival of the replaced joint for longer term.

And the newer cement-less designs have better integration into the bone and enable to get fixation without cement, thereby nullifying cement related problems.

If you have hip problems in early age, do visit your orthopaedic surgeon to find a right solution. Timely treatment could help delay surgery and maintain good quality active life.

Go here to read the rest:
Combating arthritis: How to deal with this crippling disease - Free Press Journal

Read More...

Global Psoriatic Arthritis Therapeutics Market To Witness Towering Growth And Surpass USD 16.71 Billion By 2025 – Bandera County Courier

Thursday, March 19th, 2020

Zion Market Researchalways aims at offering their clients an in-depth analysis and the best research material of the various market. This new report on theGlobal Psoriatic Arthritis Therapeutics Market Is Expected To Reach Around USD 16.71 Billion By 2025is committed fulfilling the requirements of the clients by giving them thorough insights into the market. The Psoriatic Arthritis Therapeutics Market report, titled Psoriatic Arthritis Therapeutics Market, is expansive research reliant on Psoriatic Arthritis Therapeutics Market, which inspects the raised structure of the present Psoriatic Arthritis Therapeutics Market all around the globe. Arranged by the adequate methodical framework, for instance, SWOT examination, the Psoriatic Arthritis Therapeutics Market report exhibits a total evaluation of the significant players of thePsoriatic Arthritis Therapeutics Market. The estimates for CAGR (Compound Annual Growth Rate) is calculated by the Psoriatic Arthritis Therapeutics Market report in terms of extent for the specific time length. This will similarly help the customer with comprehension and settle on a correct choice depends on a normal chart.

Request Free Sample Report of Psoriatic Arthritis Therapeutics Market Report @https://www.zionmarketresearch.com/sample/psoriatic-arthritis-therapeutics-market

Some of the Major Psoriatic Arthritis Therapeutics Market Players Are:

AbbVie, Amgen, Celgene Corporation, Janssen Biotech, UCB, Pfizer, Biogen, Novartis AG, Eli Lilly and Company

This report similarly comprises of the bifurcation of the Psoriatic Arthritis Therapeutics Market by the type of product, its end-users, applications, and others . Moreover, Psoriatic Arthritis Therapeutics Market report gives an arrangement regard to the Psoriatic Arthritis Therapeutics Markets components, by pinpointing a couple of edges including limitations, regard chain, utilization foundation, and client affirmation. The Psoriatic Arthritis Therapeutics Market report is assembled of direct experiences isolated from the emotional and quantitative assessment by Psoriatic Arthritis Therapeutics Market agents, competition between them, strategies, Psoriatic Arthritis Therapeutics Marketing, production, research, and development. Moreover, Psoriatic Arthritis Therapeutics Market report addresses a methodical appraisal of macroeconomic markers, parent Psoriatic Arthritis Therapeutics Market inclines and developed components together with the Psoriatic Arthritis Therapeutics Market.

Also, the emotional effect is charted by the examination of different provincial regions[Latin America, North America, Asia Pacific, Middle & East Africa, and Europe]together with segments. The Psoriatic Arthritis Therapeutics Market globally is the cornerstone of the development angles and prospects, as the improvement of a specific arrangement needs numerous mechanically upheld hypothesis, thoughts, and systems. The Psoriatic Arthritis Therapeutics Market report contains in general successful system, confinements, and top to bottom illumination of the past information alongside the present and future needs that might concern the development. The Psoriatic Arthritis Therapeutics Market report affirms an exhaustive synopsis of the present development, variables, enumerating, and creation. The Psoriatic Arthritis Therapeutics Market report additionally conveys a total dynamic of the money related good and bad times concerning request rate and satisfaction proportions.

Download Free PDF Report Brochure @https://www.zionmarketresearch.com/requestbrochure/psoriatic-arthritis-therapeutics-market

Promising Regions & Countries Mentioned In The Psoriatic Arthritis Therapeutics Market Report:

Following 15 Chapters represents the Psoriatic Arthritis Therapeutics Market globally:

At last, the global Psoriatic Arthritis Therapeutics Market gives the readers a complete view of the market during the forecast period from 2020-2026 which will assist them in making right business choices that will lead to development the development of their company.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/psoriatic-arthritis-therapeutics-market

Worldwide Psoriatic Arthritis Therapeutics Market Report Provides Comprehensive Analysis of:

Questions covered in Worldwide Psoriatic Arthritis Therapeutics Market Industry research report:

What are current global Psoriatic Arthritis Therapeutics Market market tendencies, obstructions, and challenges faced by the key competitors of Psoriatic Arthritis Therapeutics Market market?

What are major outcomes and consequences of the five strengths study of Psoriatic Arthritis Therapeutics Market industry?

What will be the Psoriatic Arthritis Therapeutics Market market capacity and growth estimation forecast up to 2026?

Who are the major players in the world Psoriatic Arthritis Therapeutics Market market and what ways they follow to increase overall revenue?

What are the durabilities and defects of the Psoriatic Arthritis Therapeutics Market industry?

Request Report TOC (Table of Contents) @https://www.zionmarketresearch.com/toc/psoriatic-arthritis-therapeutics-market

Reasons to buy:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Follow this link:
Global Psoriatic Arthritis Therapeutics Market To Witness Towering Growth And Surpass USD 16.71 Billion By 2025 - Bandera County Courier

Read More...

Gerth: Coronavirus outbreak will take its toll, but we’ll get through it as we always have – Courier Journal

Thursday, March 19th, 2020

With a viral outbreak prompting the WHO to declare a global health emergency, let's take a look at what a coronavirus is. Louisville Courier Journal

There are points in our history that we'll always remember.

For some, it was the Kennedy assassinations. Both of them. Or when MLK was gunned down. For others, the Nixon resignation. Or the Challenger explosion, or the attack on the World Trade Center.

We can now add the coronavirus to the list of events that have changed our outlooks, inexorably altered the path of our country and forced us to take stock in our own lives.

"I'm shaking," said Frank Foster, ashe held court Thursday at the big round table in the middle of Franco's Restaurant, which he opened13 years ago. He admitted feeling helpless if the pandemic spikes here as it did in Wuhan, China, and Milan.

"I wouldn't know what to do," the 78-year-oldsaid."I've never been through anything like this before."

There's a good reason he was shaking. A lot of us were.

That day Thursday was the most memorable awful day of a memorable awful week.The news was filled with dire warnings from our elected officials.

Frank Foster, right, the owner of Franco's, said he is "shaking" because of the coronavirus.(Photo: Joseph Gerth)

[Want to know all the Kentucky-related coronavirus news? Download our app.]

That day saw the Dow Jonesplummet2,353 points the worst drop since the stock market crash of 1987. It saw schools throughout the state begin to close as we try to protect our children from catching the virus and bringing it home to sicken us and theirgrandparents.

That horrible day saw more and more things like plays and concerts events where we gather to have fun and celebrate life put on hold.

Considered impossible just a couple of days earlier, the Kentucky High School Athletic Association called off the Sweet Sixteen basketball tournaments.

And perhaps in the most stunning move of all for us, it saw the NCAA cancel March Madness, do away with spring sports altogether, and it saw most major professional sports suspend or delay their seasons.

By Saturday, Kentucky had at least 16 positive tests for the coronavirus.

Gov. Andy Beshear has consistently warned us that there will be more.

While we haven'thad any of the deaths here like in Washington and California and a few other states, it'shard to imagine the coronavirus hasn't stolen from each of us something we love whether it's learning or sports or our ability to retire. Or if it's just our peace of mind.

Mark Rucker, a 50-year-old real estate lawyer in Lexington, is worried.

About 80%of the people who get COVID-19 have mild or no symptoms, according to the World Health Organization. But older adults and people with serious chronic medical conditions including heart disease, kidney disease, diabetes and lung disease are at higher risk, according to the Centers for Disease Control and Prevention.

Kentucky coronavirus live updates: Get the latest information here

He's in the 20% none of us wants to be in.

Rucker has kidney disease andrheumatoid arthritis, which requires him to take a steroid that suppresses his immune system.

On Monday, the news came that the first positive test for the coronavirus had been reported in Lexington. This had him especially on edge.

So on Tuesday morning, he got up and went to his kidney doctor for a previously scheduled appointment.

"I wore an N95-rated mask to my appointment for the first time ever," he said. "I did feel slightly awkward but again, being around other immune-compromised individuals just really made me think 'better safe than sorry.'"

It's scary for many people.

State officials are telling people to stay away from crowds. They're telling us to keep 6 feet between us and others. It's up to that distance that a cough or a sneeze will pose a risk to others. If you're over age 60 or in poor health, you're told not to get on a plane, and for gosh sakes, everyone stay away from cruise ships.

Employers are telling many of us not to go to the office where we can spread the disease. I'll be filing columnsfrom my recliner most days for the next few weeks; my wife will be on her computer across the room; and my daughter will probably be holed up in her bedroom.

Apple Stores have shut down. Others will likely follow.

Some people have gone overboard. Fear has caused them to hoard groceries and toilet paper.

Coronavirus tracker: How manycases are in Kentucky? Where are they?

Autoplay

Show Thumbnails

Show Captions

This will go on for weeks, if not months, as a vaccine isn't expected to be ready until later this year.

The dregs of society are trying to profiteer. One man in Tennessee had amassed 17,700 bottles of hand sanitizer and was selling them for many times their original value before Amazon and eBay stopped price gouging on their platforms, The New York Times reported.

Heshould choke on a bottle of Purell.

Hoarding begets hoarding. Others started buying up everything in groceries. Pasta. Bread. Rice. Toilet paper. Hand soap. Lysol Wipes. Even fresh fruit, which one would think would rot before hoarders eat it, was wiped out in grocery stores.

At Kroger on Friday, I looked around at the empty shelves and felt I knew what it was like to live in the old Soviet Union.

Delta Air Lines announced Friday that it was grounding 40% of its flights as people avoidcommercial carriers.

For someone like Mike Goetz, deciding whether to travel or to be in large crowds could be a life or death decision. He was diagnosed with leukemia about a year ago.

Because of the virus, Goetz and his wife have decided not to fly to Palm Springs, California, this month for a family vacation they had been planning.

My hematologist said, I dont want you on a plane right now. I dont think its prudent,'" Goetz said.

Now, the family is struggling about whether to cancel his daughters March 28 wedding in Nashville, Tennessee.

"Ive had quite a few older family members inform me in the last few days that they wouldnt be coming, he said. Ive never seen such a fluid situation and things changing so quickly in my life.

Read more: Louisville stores flooded by shoppers panicked over coronavirus

Steve Hankins, of Shepherdsville, isn't going to be traveling either.

He was in Saugus, Massachusetts, on business last weekend when he fell ill.

A cough. Shortness of breath. Fever.

He awoke in his hotel room last Sunday morning and drove his rental car to Massachusetts General Hospital and asked a security guard outside where he could find the emergency room.

"STAND RIGHT HERE!" was the order.

Within minutes, someone from the ER gave him a mask and escorted into an isolation room, where doctors began working to figure out what was going on. They determined he had chronic obstructive pulmonary disorder and a bad case of the flu and admitted him to the hospital.

Back in Shepherdsville, his wife was frantic.

Also: As coronavirus fears spread, these small businesses stand to lose big

Why wasn't Hankins, who travels by commercial plane several times a month and passes through airports often,tested for the coronavirus?

The fact is, there just aren't enough tests to go around. People who should be tested aren't being tested.

Only about 150 people in Kentucky have been testedbecause the federal government was slow to react to the burgeoning crises. Because of that, hundreds, or even thousands, of people may be unwittingly spreading the virus in Kentucky.

The virus has interfered with even the simple things in life.

Churches have canceled services.

People are not allowed to visit family in nursing homes unless their loved ones are near death. The rules, necessary to keep the virus away from those most vulnerable to it, are certainly increasing the loneliness and isolation that is already a problem the elderly face.

Some restaurants are empty.

On Friday, Hooked on Frankfort, a fish restaurant within 1.8 miles of five Catholic churches, had only about 15 people eating there at 12:30 p.m. On a Friday. During Lent.

College and university closures were affecting high school students who were planning trips to campuses across the country.

Elise Williamson, a 17-year-old senior at duPont Manual High School,said she learned at about 11 a.m. Tuesday her visit to Yale next month wouldn't happen. She was scheduled to go to New Haven, Connecticut, to learn about financial assistance available to her and then to attend Bulldog Days a three-day orientation program for admitted students.

They were canceling because of the coronavirus, just because of how many students would be coming there, not just from across the country but from around the world, she said.

Williamson said shes disappointed because she thought the orientation programwould have eased her transition to college life, but she said shes in a better position than many students because she was able to visit campus last summer.

Elise Williamson is a senior at Manual High School. She'll be attending Yale University in the fall and had planned an upcoming visit to the school, but it was canceled due to coronavirus precautions.(Photo: Pat McDonogh, Courier Journal)

Dive deep: With coronavirus kits limited, Kentucky is testing only the sickest patients

Law schools at Harvard and University of California, Berkeley, havesaid they aren't sending students to a program at the Appalachian Research & Defense Fund, AppalReD, that helps poor people with their legal troubles and provides an important learning experience for the future lawyers.

On Saturday morning, students at Bellarmine University packed up their belongings and loaded them into cars ordered by the school to vacate the dormitories this weekend.

Wiley Carr III needed only three bags to move out of his dorm room at Bellarmine University: One had his laptop and other class materials. One had some personal hygiene products. The third carried his trumpet.

I understand the safety precautions, Carr,23,said. But this impacts so many students.

Wiley Carr III carried a few belongings after checking out of his dorm on the campus of Bellarmine University on Saturday.(Photo: Sam Upshaw Jr./Courier Journal)

Beshear, who's shown a steady hand warning of the dangers of the virus, has been careful to say at each press conference he's held that "we will get through this."

It's no doubt we will. But it will take its toll.

But we will be forever changed.

We'll think twice about shaking hands for a long time. We'll worry about the next new disease that comes along. And we'll worry if our government will be able to deal with it if it does.

But, as Beshear says, we will get through this.

Information for this column was also gathered by Jonathan Bullington.Joseph Gerthcan be reached at 502-582-4702 or by email atjgerth@courierjournal.com. Support strong local journalism by subscribing today:courier-journal.com/josephg.

Read or Share this story: https://www.courier-journal.com/story/news/local/joseph-gerth/2020/03/14/gerth-covid-19-take-toll-but-well-get-through/5009893002/

Read more:
Gerth: Coronavirus outbreak will take its toll, but we'll get through it as we always have - Courier Journal

Read More...

Examining Treatment Options for Statin-Induced Anti-HMGCR Myopathy – Rheumatology Advisor

Thursday, March 19th, 2020

An initial triple steroid/intravenous immunoglobulin (IVIG)/steroid-sparing immunosuppressant (SSI) induction strategy was effective for the treatment of statin-induced anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (anti-HMGCR) myopathy, according to study results published in Arthritis Research & Therapy. In addition, early treatment initiation was associated with greater odds of successful maintenance with SSI monotherapy.

Investigators abstracted data from the Phenotype, Serology, and Successful Monotherapy Maintenance in Autoimmune Myositis (PHESMO) study, a retrospective study of patients with autoimmune myositis who received care at 2 participating hospitals in Quebec, Canada. Patients were followed up longitudinally between 2001 and 2018. The current analysis used data from patients with statin-induced anti-HMGCR myopathy, defined as having a positive anti-HMGCR autoantibody test, elevated serum creatine kinase levels, and proximal skeletal muscle weakness. Demographic and clinical data were extracted through medical record review, and therapeutic strategies used to combat anti-HMGCR myopathy were assessed. Multivariate logistic regression was performed to identify predictors of maintenance with SSI monotherapy. Sensitivity analyses adjusted for age, sex, strength, creatine kinase levels, dysphagia, and corticosteroid use.

Data from 55 patients with anti-HMGCR myopathy were used for the study. Median age at diagnosis was 67.7 years; 95% of patients were white; and 72% had diabetes mellitus. The most commonly prescribed statin was atorvastatin (84%). Statin therapy was discontinued in all patients. At initiation of anti-HMGCR myopathy treatment, 46 patients (84%) presented with proximal weakness, 48 (87%) had biopsy evidence of necrotizing myopathy, and all patients were positive for anti-HMGCR autoantibodies. Median creatine kinase elevation was 5000 U/L (range, 554-23,000 U/L).

Overall, 14 patients (25%) achieved remission with a corticosteroid-free induction strategy. The remaining 41 patients were treated with corticosteroids, either through dual steroid/SSI induction (n=19) or triple steroid/IVIG/SSI induction (n=22). A total of 4 patients failed the initial triple steroid/IVIG/SSI induction strategy, with all 41 patients achieving remission eventually. A corticosteroid-free SSI monotherapy maintenance strategy was successful in 73% of patients initially treated with corticosteroids.

Greater treatment delay predicted lower odds of successful maintenance with SSI monotherapy (odds ratio, 0.92; 95% CI, 0.85-0.97; P =.015). In patients with successful SSI monotherapy maintenance (n=23) vs those without (n=18), mean treatment delays were 1.7 months and 12.7 months, respectively (P =.048).

In addition, a significant percentage of patients presented with normal strength (n=22; 40%), suggesting that anti-HMGCR myopathy has diverse clinical presentations.

While corticosteroid-free induction was a safe option for select patients, initial induction with triple steroid/IVIG/SSI was highly efficacious in the treatment of anti-HMGCR myopathy. Success with SSI monotherapy appeared to favor early intervention. [A]voiding delays in treatment, most notably in patients with normal strength, may reset the natural history of anti-HMGCR myopathy from a refractory entity to a treatable disease, the investigators wrote.

Reference

Meyer A, Troyanov Y, Drouin J, et al. Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res Ther. 2020;22(1):5.

Read the original:
Examining Treatment Options for Statin-Induced Anti-HMGCR Myopathy - Rheumatology Advisor

Read More...

Learn global specifications of the Psoriatic Arthritis Treatment Market – Monroe Scoop

Thursday, March 19th, 2020

The Psoriatic Arthritis Treatment market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Psoriatic Arthritis Treatment market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Psoriatic Arthritis Treatment market study provides reliable and authentic projections regarding the technical jargon.

Psoriatic Arthritis Treatment Market Research, in its recent market report, suggests that the Psoriatic Arthritis Treatment market report is set to exceed US$ xx Mn/Bn by 2029. The report finds that the Psoriatic Arthritis Treatment market registered ~US$ xx Mn/Bn in 2018 and is spectated to grow at a healthy CAGR over the foreseeable period. This Psoriatic Arthritis Treatment market study considers 2018 as the base year, 2019 as the estimated year, and 2019 2029 as the forecast timeframe.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2237281&source=atm

The Psoriatic Arthritis Treatment market study answers critical questions including:

The content of the Psoriatic Arthritis Treatment market report includes the following insights:

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2237281&source=atm

The key players covered in this studyEli LillyRocheMerckNovartisAbbvieAmgenBristol Myers SquibbCelgene CorporationJanssenValeant Pharmaceuticals

Market segment by Type, the product can be split intoKitsReagentsInstruments

Market segment by Application, split intoHospitalsClinicsAmbulatory Surgery CentersDiagnostic Laboratories

Market segment by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Psoriatic Arthritis Treatment status, future forecast, growth opportunity, key market and key players.To present the Psoriatic Arthritis Treatment development in United States, Europe and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Psoriatic Arthritis Treatment are as follows:History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

All the players running in the global Psoriatic Arthritis Treatment market are elaborated thoroughly in the Psoriatic Arthritis Treatment market report on the basis of R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines, legal policies, and comparative analysis between the leading and emerging Psoriatic Arthritis Treatment market players.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2237281&licType=S&source=atm

Why choose Psoriatic Arthritis Treatment market Report?

For More Information Kindly Contact:

marketresearchhub.com

Mr. Nachiket Ghumare,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Read the rest here:
Learn global specifications of the Psoriatic Arthritis Treatment Market - Monroe Scoop

Read More...

Rheumatoid Arthritis Therapeutics Market 2020 Size, Growth Forecast to 2026 – Press Release – Digital Journal

Thursday, March 19th, 2020

Rheumatoid Arthritis Therapeutics Industry 2020 Global Market Outlook To 2026

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 03/18/2020 -- Rheumatoid Arthritis Therapeutics Market Trends report provides detailed analysis and competitive analysis by region and other main information like a manufacturing process, raw material, and equipment suppliers, various manufacturing associated costs, historical & futuristic cost, revenue, demand and supply data, the actual process. Rheumatoid Arthritis Therapeutics report offers a detailed analysis of the industry, with market size forecasts covering the next four years. The Report contains complete coverage, intensive analysis, and actionable market insights to spot opportunities in existing and potential markets.

Market Analysis and Insights: Global Rheumatoid Arthritis Therapeutics Market. The global Rheumatoid Arthritis Therapeutics market, growing at a CAGR. Global Rheumatoid Arthritis Therapeutics Market: Drivers and Restrains The research report has incorporated the analysis of different factors that augment the market's growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones.

Get Sample Rheumatoid Arthritis Therapeutics Market Report

This section also provides an analysis of the volume of production about the global market and also about each type from 2015 to 2026. This section mentions the volume of production by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026.A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert's opinions have been taken to understand the market better.

The Global Rheumatoid Arthritis Therapeutics Industry 2020 Global Market research provides a basic overview of the industry including definitions, classifications, applications, and industry chain structure. The Global Rheumatoid Arthritis Therapeutics market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue, and gross margins.

The Global analysis is provided for the international markets including development Rheumatoid Arthritis Therapeutics market trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue, and gross margins.

The report also focuses on global major leading industry players of Global Rheumatoid Arthritis Therapeutics market providing information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out. The Global Rheumatoid Arthritis Therapeutics market development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

With tables and figures helping analyze worldwide Global Rheumatoid Arthritis Therapeutics market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The report also focuses on global major leading industry players of Global Rheumatoid Arthritis Therapeutics market providing information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue and contact information. This report focuses on Rheumatoid Arthritis Therapeutics volume and value at a global level, regional level, and company level. From a global perspective, this report represents the overall Rheumatoid Arthritis Therapeutics market size by analyzing historical data and future prospects.

The Medical Transcription market has been created based on an in-depth market analysis with inputs from industry experts. The report covers the growth prospects over the coming years and discussion of the key vendors. The report provides a comprehensive analysis of key factors that are expected to drive the Medical Transcription Market growth.

About us:Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Contact Us:

Fortune Business Insights Pvt. Ltd.

Supreme Headquarters,

Pune Banglore Highway, Baner, Pune,

Maharashtra 411045, India

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com

For more information on this press release visit: http://www.sbwire.com/press-releases/rheumatoid-arthritis-therapeutics-market-2020-size-growth-forecast-to-2026-1282817.htm

Read the original:
Rheumatoid Arthritis Therapeutics Market 2020 Size, Growth Forecast to 2026 - Press Release - Digital Journal

Read More...

Worldwide Analysis on Psoriatic Arthritis Therapeutics Market Strategies and Forecasts, 2019 to 2025 – Daily Science

Thursday, March 19th, 2020

A report on global Psoriatic Arthritis Therapeutics market by PMR

The global Psoriatic Arthritis Therapeutics market report scrutinizes the market behavior and the manner in which the market has been performing and responding to various situations. Starting with some basic definitions associated with Psoriatic Arthritis Therapeutics , the report progresses to various analyses (DROT and Porters Five Forces) for evaluating the positive and negative factors impacting market growth.

The market report breaks down the Psoriatic Arthritis Therapeutics market into various segments product type, end use, and region and market players. Market shares of each segment is depicted accurately along with the factors responsible for them.

Key insights of the Psoriatic Arthritis Therapeutics market report:

Request Sample Report @ https://www.persistencemarketresearch.co/samples/13729

key players and product offerings

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/13729

The Psoriatic Arthritis Therapeutics market addresses the questions, such as

Why choose PMR:

PMR provides business reports on regional as well as country basis. We leverage new-age industrial tools to perform error-free analysis of ongoing trends in various verticals. Our analysts approach trustworthy sources to gather accurate information regarding the market. Clientele can approach our team at any hour of the day to get facilitated.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/13729

About us:

PMR is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

See the original post here:
Worldwide Analysis on Psoriatic Arthritis Therapeutics Market Strategies and Forecasts, 2019 to 2025 - Daily Science

Read More...

Arthritis drug to be tested to treat coronavirus – MarketWatch

Tuesday, March 10th, 2020

Drugmakers Regeneron Pharmaceuticals Inc. and Sanofi SA are racing to launch clinical trials exploring whether their arthritis drug could treat symptoms of novel coronavirus infections.

The study preparations mark the latest effort in an emerging front in researchers' hunt for effective treatments for Covid-19, the respiratory disease caused by the novel coronavirus. In the U.S., there aren't any drugs or vaccines approved for the condition.

The research aims to see whether certain drugs already on the market to tackle immune disorders like rheumatoid arthritis could help ease damage to the lungs and respiratory system caused by the immune system's overreaction to the Covid-19 virus, rather than killing it.

The Sanofi and Regeneron drug, called Kevzara, was approved by the Food and Drug Administration in 2017 to treat rheumatoid arthritis.

"The goal would be in the next couple of weeks to have the trial up and running, and in weeks to months after that to have the data," Regeneron Chief Scientific Officer George Yancopoulos said in an interview on Tuesday.

Write to Joseph Walker at joseph.walker@wsj.com

More:
Arthritis drug to be tested to treat coronavirus - MarketWatch

Read More...

People with Rheumatoid Arthritis Have Higher Risk for Heart Disease – Healthline

Tuesday, March 10th, 2020

Its not just your joints that rheumatoid arthritis can affect.

It can also affect your heart.

A new study published in the journal RMD Open concluded that the presence of rheumatoid arthritis (RA) may be associated with an increased risk of major adverse cardiovascular events, also known as MACE.

The researchers said the increased association was more common in cases of RA that are either seropositive or considered to be active.

In the study, the researchers assessed this risk for MACE and death in people with RA who were required to have a cardiac CT scan for chest pain.

In patients referred to cardiac CT due to chest pain, we found a trend of an association between RA and the combined primary outcome, supporting that RA per se, but in particular seropositive and active RA, may increase the risk [for coronary artery disease] even after initial [coronary artery disease] diagnosis and treatment, the researchers said in a statement.

The data used for this registry was obtained from the Western Denmark Heart Registry and Danish National Patient Registry between 2008 and 2016.

The outcome of the study found a mix of cardiac events, such as myocardial infarction, percutaneous coronary intervention, ischemic or unspecified stroke, coronary artery bypass grafting, and other causes of death.

The Arthritis Foundation has noted this association between MACE and RA in the past.

According to the Arthritis Foundation, people with RA face a 50 to 70 percent higher risk for cardiovascular disease than the general population.

In addition, people with osteoarthritis face a 24 percent higher risk for cardiovascular disease than the general population.

Overall, the foundation reported, nearly half of all adults with heart disease also have some form of arthritis.

Women also have a higher risk for both heart disease and rheumatoid arthritis. They sometimes face gender disparities in treatment for heart health issues and chronic pain.

Certain foods, such as seafood, and supplements, like fish oil and essential omega fatty acids, can help with both heart health and the inflammation of arthritis.

People living with RA should consult their doctor if they experience any new symptoms, want more information on heart health, or want to try out any new supplements or vitamins as a part of their treatment regimen.

The Arthritis Foundation and other experts recommend exercise as part of an overall balanced and healthful lifestyle of wellness for people with arthritis.

There are many health benefits to exercising, even with arthritis, Kindle Fisher, a physical therapist in Pennsylvania, told Healthline.

Exercises such as walking, swimming, or using a stationary bike can increase blood flow and synovial fluid to the joints. Increasing blood flow will also strengthen the heart, she said. While there are severe cases of arthritis where its not always possible to do so, any type of activity can release endorphins, improve health, and help you feel better overall.

People with RA say its important to keep a watch on their heart health but also to try to have a normal life.

I became educated on how unchecked inflammation increases the risk of heart disease, including the risk of heart attack and stroke, Sandra S. of British Columbia, Canada, told Healthline.

Knowing this has allowed me to make more informed decisions when it comes to my health and highlights the importance of managing inflammation effectively, she said.

William A. of Pittsburgh, Pennsylvania, notes that while cardiovascular risk is a concern, it doesnt consume his life.

I became aware of the correlation between heart disease and RA just last year. I was first diagnosed with Sjgrens syndrome in 2009, and my RA diagnosis came just 2 years ago, he told Healthline.

My heart has always worked extra hard and beat extra fast, but Im lucky to have managed my blood pressure for the most part. It is a concern of mine, but I only really think about it when I am symptomatic, he said.

Im grateful to have the information about a link with heart disease and rheumatoid disease, and I do see it in my work, Cynthia S, a nurse from Philadelphia who has rheumatoid arthritis, told Healthline.

But I feel if I continue to try to live a healthy lifestyle even with these health issues, I will thrive, she said.

Go here to see the original:
People with Rheumatoid Arthritis Have Higher Risk for Heart Disease - Healthline

Read More...

Monday Medical: Thumb arthritis things to know – Steamboat Pilot & Today

Tuesday, March 10th, 2020

If everyday actions, such as opening a jar, have become painful, you just might be dealing with thumb arthritis.

Thumb arthritis affects one in every three women, said Dr. Patrick Johnston, an orthopedic surgeon in Steamboat Springs and a member of the medical staff at UCHealth Yampa Valley Medical Center. It also affects men, but not as frequently. Overall, its one of the most common conditions that brings patients into the office.

Below, Johnston outlines what you need to know about thumb arthritis.

The base of the thumb and wrist meet at the basal or CMC joint, commonly called the saddle joint.

When you pinch with your fingertips, the force in that joint is 13 times what it is at the fingertips, Johnston said. Over years of pinching, you stretch out the ligament that holds the thumb in the saddle joint, so the thumb no longer sits in the middle of the saddle.

That causes an extra load on the joints cartilage the strong, flexible tissue that provides padding at the joints. Eventually, that cartilage can wear out.

Arthritis is the progressive loss of cartilage, and its irreversible, Johnston said. Like tread on the tires, once it wears off, you cant put it back on.

Thumb arthritis cant be prevented, but genetics play a role: if one of your parents had thumb arthritis, you are more likely to suffer from the condition.

The most common complaint is pain at the base of the thumb when pinching things, especially when trying to open a jar. The pain may also be felt in the palm of the hand.

Thumb arthritis can begin as early as age 40. Eventually, the pain may go away on its own.

Over time, the pain from thumb arthritis tends to improve, Johnston said. It may take several years, but that pain can kind of burn out. But not everybody makes it to that point.

When dealing with arthritis, the goal is to alleviate pain.

I dont treat the X-ray, I treat the patient, Johnston said. If a patient has arthritis on an X-ray but isnt experiencing pain, were happy. Im concerned with their pain level and how its affecting their life. I want patients to be able to live the lifestyle they want, and Ill do whatever I can to help get them to that point.

To ease pain, Johnston recommends running the hand under warm water, taking anti-inflammatory medications if tolerated and trying natural supplements, such as tart cherry juice and turmeric, both of which have anti-inflammatory properties.

Another option is using a thumb splint, which is designed to support the thumb during aggravating activities, such as gardening and pulling weeds.

If those steps arent enough, a steroid injection may help. And finally, theres surgery.

Surgery is a good option for patients who are experiencing pain thats severe enough to affect their daily activities and quality of life and who are not improving with conservative treatment options, Johnston said.

While there are many surgical techniques for thumb arthritis, Johnston prefers one thats been around since the 1940s.

Its a tried and true technique with great long-term results, Johnston said. It has a very high success rate and a low complication rate.

In the 45-minute procedure, Johnston makes a little incision in the wrist to remove the small wrist bone that causes the pain, then uses a tendon from the forearm to reconstruct the ligament thats been stretched out. The patient wears a removable splint for six weeks, then can resume activities as tolerated.

Not necessarily. Other issues can cause similar pain, but thumb arthritis is the most common culprit.

If youre having pain in the base of your thumb, its probably worth having an evaluation, Johnston said. We can get an X-ray and help determine whats going on.

Susan Cunningham writes for UCHealth Yampa Valley Medical Center. She can be reached at cunninghamsbc@gmail.com.

Link:
Monday Medical: Thumb arthritis things to know - Steamboat Pilot & Today

Read More...

TV host and comedian Matt Iseman says he was a "shell of himself" living with arthritis – WSAW

Tuesday, March 10th, 2020

(WZAW) -- Imagine not being able to hold your newborn baby or being thrown into a vicious cycle of unemployment through no fault of your own. Thats the reality for many of the 54-million Americans living with arthritis.

Arthritis is the number one cause of disability in the United States. The results of one the nations largest assessments of people with arthritis, called A Mandate for Action, reveals the devastating physical and emotional realities for those living with arthritis.

Some of the shocking revelations from the survey include:

- Physical Pain: 100% of patients registered pain so significant it effects their day-to-day lives, causing major lack of mobility and chronic fatigue. And not the kind of pain that can be easily managed, but significant pain that is disrupting sleep, causing isolation and leading to depression and anxiety.

- Life-Altering Emotional Effects: 72% reported having trouble doing all usual work including work from home.

- Gap in Quality Care: Only 57% of patients report being able to get the help they need during their healthcare appointments.

Comedian and TV host Matt Iseman lives with rheumatoid arthritis. He shared his story living with the chronic condition on NewsChannel 7 at 4, along with Cindy McDaniel, the senior vice president of consumer health for the Arthritis Foundation.

Its been almost 20 years that Ive been living with rheumatoid arthritis, but it was the first 18 months that were the most devastating, because thats when the disease started taking over my body, Iseman said.

Iseman went on to say that the pain started in his right index finger but eventually spread to the other joints in his hands, his feet, neck and back.

I was also fatigued. I was sleeping 10, 12 hours a day and still felt like I had no energy. I became a shell of myself," he added.

McDaniel said emotional pain can often equal the physical pain of the disease.

People become socially isolated, they become depressed, theres a lot of anxiety. Part of the assessment looks at these effects, she said.

Once Iseman got his diagnosis and on a treatment plan, he said he got his life back. Since then, hes been working with the Arthritis Foundation to be an advocate for the 50 million Americans live arthritis to get treatment and a better life.

For more information, visit http://www.Arthritis.org/Insights

Go here to read the rest:
TV host and comedian Matt Iseman says he was a "shell of himself" living with arthritis - WSAW

Read More...

The misconception that arthritis only affects the elderly – Gulf News

Tuesday, March 10th, 2020

Image Credit: iStock

In the UAE, one in 10 adults suffer from arthritis. With its high prevalence, there is a common misconception that arthritis is a condition that only affects the elderly and adults. This isnt the case though. Juvenile idiopathic arthritis (JIA) can affect children that are as young as six months old, up to the age of 16. Some children can experience the symptoms for a few months and others can have the symptoms for the rest of their lives. Globally, JIA affects around one in 1,000.

Dr Anand Gorva, Specialist Paediatrics Orthopaedics, Medcare Orthopaedics & Spine Hospital, says that JIA, like rheumatoid arthritis, is autoimmune-related and causes inflammation and pain and stiffness in the joints. JIA is an autoimmune disease or it is when the immune system malfunctions against the lining of the joints, called the synovial membrane.

Dr Gorva says that although the exact cause of the condition is unknown, it is associated with a number of factors. It is genetic disorder and risk factors include exposure to environmental factors, such as pollution. He says that smoking, infections, a lack of exercise and a poor diet can also be risk factors.

Dr Ajith Jose, Specialist Orthopaedics, Aster Hospital, Qusais, says that the majority of cases of JIA arent inherited. Most cases of JIA are sporadic, which means they occur in people with no history of the disorder in their family. A small percentage of cases of JAI have been reported to run in families, although the inheritance pattern of the condition is unclear.

A sibling of a person with juvenile idiopathic arthritis has an estimated risk of developing the condition that is about 12 times that of the general population. Dietary and emotional factors do not appear to play a role in the development of JIA. Researchers have also identified changes in several genes that may influence the risk of developing JAI.

Lack of awareness

Dr Gorva says that peoples lack of awareness about JIA means that it is often diagnosed late or missed. Most people assume that arthritis is an adult disorder and cant happen in children therefore they present late to the doctors. This lack of awareness delays the presentation time when compared to adults. Schools need to be informed and encourage the child to participate in extra-curricular activities as normal as possible. Occupational therapists should liaise with school-based therapists for the continuation of care for these children.

He says that diagnosing JIA at an early stage means that the child is more likely to be receptive to the treatment and less likely to face complications. If the treatment is started early, the response is good and it can prevent major complications such as joint destruction and functional disability.

Dr Jose says that another issue is that JIA can be tricky to diagnose. Diagnosis of juvenile idiopathic arthritis can be difficult because joint pain can be caused by many different types of problems. No single test can confirm a diagnosis, but tests can help rule out some other conditions that produce similar signs and symptoms.

He refers to different measurements that can be taken from blood tests, such as the erythrocyte sedimentation rate (ESR), which can be indicative of inflammation. The blood can also be tested for antibodies such as cyclic citrullinated peptide (CCP) and the rheumatoid factor.

Treatment

For some JIA patients, symptoms can be controlled by taking normal anti-inflammatory tablets to reduce the inflammation. Other patients need to take stronger medication which modulate the immune system. For flare-ups management, doctors may also use cortisone, also called corticosteroids or steroids, says Dr Jose.

Corticosteroids such as prednisone may be used to control symptoms until another medication takes effect. They are also used to treat inflammation when it is not in the joints, such as inflammation of the sac around the heart (pericarditis).

He says that nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen sodium, can be prescribed to reduce pain and swelling.

If NSAIDs fail to relieve the symptoms of pain or swelling or the patient is at a high risk of future complications, Dr Jose says that disease-modifying antirheumatic drugs (DMARD) can be prescribed.

These type of medicines can modulate the immune system to control the disease progression. The most commonly used DMARD for children is methotrexate.When only a few joints are involved, a steroid can be injected into the joint before any additional medications are given.

Dr Jose also refers to new classes of drugs called biologic agents. Also known as biologic response modifiers, this newer class of drugs includes tumor necrosis factor (TNF) blockers, such as etanercept and adalimumab. These medications can help reduce systemic inflammation and prevent joint damage.Physiotherapy and support splints are also used when necessary.

Complications

JIA is associated with multiple deformities in more than half of patients, says Dr Jose. Among these deformities, hand and wrist are the commonest involved joints followed by knee joints. These deformities are statistically significantly associated with polyarthritis, seropositivity, and late presentation of patients to tertiary care.

While early diagnosis is vital, JIA can also disrupt a childs growth and bone development and some medications, such as corticosteroids, can also inhibit growth. Yet, Dr Gorva says that the emotional impact of the condition should also be considered.

Apart from functional disabilities like joint contracture and stiffness the child can have emotional, psychological and social problems. Therefore a multi team approach would mitigate these problems and most of the children with JIA lead an active life and do things as their peers do, he says.

See more here:
The misconception that arthritis only affects the elderly - Gulf News

Read More...

The psoriatic arthritis treatment market was valued at $7,860 million in 2018, and is estimated to reach at $13,744 million by 2026, registering a…

Tuesday, March 10th, 2020

NEW YORK, March 9, 2020 /PRNewswire/ --

Psoriatic Arthritis Treatment Market by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type (Prescription, and OTC), and Route of Administration (Topical, Oral, and Injectable): Global Opportunity Analysis and Industry Forecast, 20192026

Read the full report: https://www.reportlinker.com/p05868979/?utm_source=PRN

The psoriatic arthritis treatment market was valued at $7,860 million in 2018, and is estimated to reach at $13,744 million by 2026, registering a CAGR of 7.2% from 2019 to 2026.

Psoriatic arthritis is an autoimmune disease caused by an attack of body's immune system on skin and joint. The disease is characterized by stiffness, swelling in the joints, and pain. Symmetric psoriatic arthritis, asymmetric psoriatic arthritis, spondylitis, distal psoriatic arthritis, and arthritis mutilans are the different types of psoriatic arthritis. Symptoms associated with this disorder include low back pain, conjunctivitis, swollen joint, nail pitting, and foot pain. The disorder is more prevalent among patients already suffering from psoriasis. Psoriatic arthritis can be diagnosed with tests such as rheumatoid factor (RF), joint fluid test, X-ray, and magnetic resonance imaging (MRI). Drugs used to treat psoriatic arthritis disease include NSAIDs, disease-modifying antirheumatic drugs (DMARDs), biologics, immunosuppressant drugs, and others.

Significant increase in prevalence of psoriatic arthritis, rise in demand for psoriatic arthritis pharmacotherapy, strong pipeline of biosimilar & biologic products, stressful lifestyle resulting in the overstimulation of immune system, and rise in geriatric population are the key factors that fuel the growth of the global psoriatic arthritis treatment market. Moreover, rise in adoption of psoriatic arthritis treatment medications, increase in R&D activities to develop new products for effective treatment of psoriatic arthritis, frequent product launches by key players, surge in awareness toward availability of treatment for psoriatic arthritis, and increase in risk of diseases are other factors that contribute toward the growth of the market. However, lack of standardization tools for diagnosis and high cost of treatment are expected to hamper the market growth.

The global psoriatic arthritis treatment market is segmented into drug type, type, route of administration, and region. By drug type, the market is categorized into NSAIDs, DMARDs, biologics, and others. On the basis of type, the market is divided into prescription, and OTC. According to route of administration, it is segregated into topical, oral, and injectable. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets. It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities. A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities. The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Drug Type NSAIDs DMARDs Biologics Others

By Type Prescription OTC

By Route of Administration Topical Oral Injectable

By Region North America o U.S. o Canada o Mexico Europe o Germany o France o UK o Italy o Spain o Rest of Europe Asia-Pacific o Japan o China o Australia o India o South Korea o Rest of Asia-Pacific LAMEA o Brazil o Saudi Arabia o South Africa o Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Company Celgene Corporation Eli Lilly And Company Johnson & Johnson Merck & Co Inc. Novartis AG Pfizer Inc. UCB S.A.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.) F. Hoffmann-La Roche AG Valeant Pharmaceuticals International, Inc. Abbott Laboratories

Read the full report: https://www.reportlinker.com/p05868979/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Continue reading here:
The psoriatic arthritis treatment market was valued at $7,860 million in 2018, and is estimated to reach at $13,744 million by 2026, registering a...

Read More...

A protein found in scorpion venom just might help take the sting out of arthritis – GeekWire

Tuesday, March 10th, 2020

One of the lead authors of the scorpion venom study, Fred Hutch staff scientist Emily Girard (center), says she hopes her work results in a therapeutic that will help a lot of people. (Fred Hutch News Service Photo / Robert Hood)

Scientists at Seattles Fred Hutchinson Cancer Research Center have identified a mini-protein in scorpion venom that can target joint inflammation in arthritic rats and theyre hoping it can do the same thing for human patients.

Its too early to say whether the technique will work as well in humans as it does in rats. But the experiments reported today in Science Translational Medicine hold the promise of delivering the benefits of steroid-based therapies for arthritis while avoiding the side effects that come with the use of those steroids.

For people with multijoint arthritis, the side effects of controlling the disease can be as bad or worse than the disease itself, Fred Hutch researcher Jim Olson, the studys senior author, explained in a news release. Steroids like to go everywhere in the body except where theyre needed most. This is a strategy to improve arthritis relief with minimal systemic side effects.

The study builds on years of study that Olson has conducted into the compounds contained in scorpion venom. One of those compounds has been found to latch onto cancer cells, providing the foundation for a startup called Blaze Bioscience. Blaze is currently testing a scorpion-derived fluorescent dye called Tumor Paint, which can help surgeons target brain tumors that would otherwise be hard to spot.

After spinning out Blaze in 2010, Olson widened the scope of his search. He and his colleagues screened dozens of mini-proteins known as peptides, looking for compounds that could cross over the blood-brain barrier. They noticed that one of the peptides, known as CDP-11R, tended to accumulate in cartilage. The researchers quickly realized that CDP-11R could be used in a targeted treatment for arthritis.

It really shows the value of playing scientifically and just doing things for the pure joy of learning, Olson said. You never know where its going to take you.

The next step involved pairing the peptide molecule with the right kind of steroid. Eventually, Fred Hutchs researchers focused on a steroid known as triamcinolone acetonide, or TAA.

When a drug that paired CDP-11R with TAA was injected into rats with arthritis, the peptide-steroid combination gravitated to the joints and eased the rats inflammation, as hoped. And if some of the drug leaked into the bloodstream, it became inactive without causing the side effects associated with steroids.

Its a pretty simple idea to take a mini-protein that naturally goes to cartilage and attach something to it so that you get targeted delivery of the drug, but it was challenging to accomplish, said one of the studys lead authors, Emily Girard, whos a staff scientist in Olsons lab at Fred Hutch. We had to learn and adapt the behavior of the mini-protein, the chemical linker and the steroid payload to make a product that would go to cartilage, stay as long as we needed it to, release the drug at the right rate, and have a local but not systemic effect.

The researchers say the technique seems promising enough to move on to human clinical trials, although additional studies with animals will need to be done first. They also suggest that CDP-11R could be used to deliver other types of drugs to a patients joints more precisely.

There is more development to be done, Girard said, but I hope that this work results in a therapeutic that will help a lot of people.

In addition to Girard and Olson, the authors of the study in Science Translational Medicine, A Potent Peptide-Steroid Conjugate Accumulates in Cartilage and Reverses Arthritis Without Evidence of Systemic Corticosteroid Exposure, include Michelle Cook Sangar, Gene Hopping, Chunfeng Yin, Fiona Pakiam, Mi-Youn Brusniak, Elizabeth Nguyen, Raymond Ruff, Mesfin Gewe, Kelly Byrnes-Blake (Northwest PK Solutions), Natalie W. Nairn and Dennis M. Miller (Blaze Bioscience), Christopher Mehlin, Andrew Strand, Andrew Mhyre, Colin Correnti, Roland Strong and Julian Simon.

The research was supported by the National Cancer Institute, Blaze Bioscience and philanthropic funding from Project Violet, the Wissner-Slivka Foundation, the Kismet Foundation, the Sarah M. Hughes Foundation, Strong4Sam, Yahn Bernier and Beth McCaw, Len and Norma Klorfine, Anne Croco and Pocket Full of Hope. The work was performed in collaboration with Blaze Bioscience, which has an ongoing collaboration and option agreement with Fred Hutch to develop optimized peptide therapeutics.

Competing interests: Olson is a founder and shareholder of Blaze Bioscience, which retains intellectual property rights to the peptides used in this research.

See original here:
A protein found in scorpion venom just might help take the sting out of arthritis - GeekWire

Read More...

Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are…

Tuesday, March 10th, 2020

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that data from the interim analysis of Piclidenoson in its Phase III clinical study is expected to be released during Q4 2020. Moreover and in line with the reports that rheumatoid arthritis (RA) drugs have been introduced for the treatment of the Coronavirus, the Company is now exploring a collaboration to look at the effect of Piclidenoson against Coronavirus. Can Fite drug candidates possess anti-viral effect protected by a US patent US7589075.

Recently, two pharmaceutical companies announced the introduction of RA drugs for the treatment of patients with Coronavirus. Gilead is conducting a clinical study in China which combines its anti-viral drug candidate Remdisivir with the old RA drug chloroquine (http://www.natap.org/2020/newsUpdates/s41422-020-0282-0.pdf). In addition, Roche has donated its Actemra anti-RA drug for the treatment of patients in China (https://www.fiercepharma.com/pharma-asia/china-turns-roche-arthritis-drug-actemra-against-covid-19-new-treatment-guidelines?mkt_tok=eyJpIjoiTVdVeU5XUmpOMlUyWkRSaCIsInQiOiJxRUtpQjhUU2U5NkJGMkxlaEdiZDhoRVFTQkkxbjJzQUV6d1hacVV3T3gzNmRZN3R5d0JWd0ZBeXhQZUo5RTN1XC91QTFIemVBekpzNHdwaGFHZGo1TmYweVgzeUdudHc1Z0R4alFYaUYyMXpVeEN1WlVTa2dSVkhqZlkxbWpkT0oifQ%3D%3D&mrkid=685430).

Can Fite is now exploring the possibility to collaborate with leading virology labs to explore the anti-viral effect of its drugs against the Coronavirus based on the known anti-viral and anti-rheumatic effects of the company drugs.

Can Fite completed the enrolment of 50% of the 525 patients planned for its Phase III ACRobat trial to evaluate its drug candidate Piclidenoson as a first-line treatment for RA. An interim analysis is being implemented, and will be managed and monitored by an independent data monitoring committee (IDMC) that will have un-blinded access to the data which are expected during Q3 2020.

Story continues

About Piclidenoson

Piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies. Piclidenoson is currently under development for the treatment of autoimmune inflammatory diseases. It is being evaluated in a Phase III study as a first line treatment, to replace methotrexate, in the treatment of rheumatoid arthritis and a Phase III study in the treatment of moderate-to-severe psoriasis.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date. For more information please visit: http://www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fites expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fites authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fites actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fites actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fites filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200305005410/en/

Contacts

Can-Fite BioPharmaMotti Farbsteininfo@canfite.com

View post:
Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are...

Read More...

Asthma, Chronic Obstructive Pulmonary Disease, and Subsequent Risk for Incident Rheumatoid Arthritis among Women: A Prospective Cohort Study – DocWire…

Tuesday, March 10th, 2020

OBJECTIVES:

Inflamed airways are hypothesized to contribute to rheumatoid arthritis (RA) pathogenesis due to RA-related autoantibody production, and smoking is the strongest environmental RA risk factor. However, the role of chronic airway diseases in RA development is unclear. We investigated whetherasthmaor COPD were associated with RA.

We performed a prospective cohort study of 205,153 women in the Nurses Health Study (NHS, 1988-2014) and NHSII (1991-2015). Exposures were self-reported physician-diagnosedasthmaor COPD confirmed by validated supplemental questionnaires. Outcomes were incident RA confirmed by medical record review by 2 rheumatologists. Covariates (including smoking pack-years/status) were assessed via biennial questionnaires. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) for RA were estimated using Cox regression.

We identified 15,148 women with confirmedasthma, 3,573 with confirmed COPD, and 1,060 incident RA cases during 4,384,471 person-years of follow-up in NHS and NHSII.Asthmawas associated with increased RA risk (HR 1.53, 95%CI 1.24,1.88) compared to noasthma/COPD after adjusting for covariates including smoking pack-years/status.Asthmaremained associated with increased RA risk among never-smokers only (HR 1.53, 95%CI 1.14,2.05). COPD was also associated with increased RA risk (HR 1.89, 95%CI 1.31,2.75). The association of COPD with RA was most pronounced in the subgroup of ever-smokers aged >55 years (HR 2.20, 95%CI 1.38,3.51).

Asthmaand COPD were each associated with increased risk for incident RA, independent of smoking status/intensity and other potential confounders. These results provide support for the hypothesis that chronic airway inflammation may be crucial in RA pathogenesis.

Read the rest here:
Asthma, Chronic Obstructive Pulmonary Disease, and Subsequent Risk for Incident Rheumatoid Arthritis among Women: A Prospective Cohort Study - DocWire...

Read More...

Turmeric seen as effective in reducing lung inflammation – indica News

Tuesday, March 10th, 2020

IANS-

Turmeric or curcumin is being advocated by some medical experts for reducing lung inflammation in the backdrop of rising Covid-19 cases in India, which is especially known to attack the respiratory system.

Turmeric is being touted as the only way to keep inflammation in your body low so that you have a better chance of fighting the coronavirus infection.

In view of the current Covid-19 epidemic and the panic around it, medical experts have a few suggestions besides washing hands, not being in crowded spaces, etc., on how to boost the immune system and possibly minimize the symptoms as there are no cures for the disease.

Vaccines are at least two years away and there are no drugs on the horizon except Actemra which is a biological drug that Roche had developed for arthritis.

Simple tricks to boost your immune system during coronavirus may help reduce the severity of the disease. One major thing that happens when you get infected is that one has a cytokine storm in the body.

Bad cytokines/hormones especially IL-6 and TNF-a levels rise which contribute to stress and organ failure during Covid-19 infection.

The pharmaceutical company Roche has dusted off an old drug, Actemra, which was developed for arthritis as it was shown to suppress IL-6. Tocilizumab (Actemra) is in a class of drugs called biologics.

Tocilizumab is a treatment for adults with moderate to severe rheumatoid arthritis (RA), giant cell arthritis, and polyarticular and systemic juvenile idiopathic arthritis.

Even if this drug is approved for Covid-19, it will cost at least $25,000-30,000 per patient. Nature has effective molecules for lowering IL-6 naturally: Turmeric/curcumin, Resveratrol and Lutein.

Turmeric/curcumin is especially excellent in reducing lung inflammation. This is the only way to keep inflammation in the body low so that one has a better chance of fighting off this infection.

View original post here:
Turmeric seen as effective in reducing lung inflammation - indica News

Read More...

Page 34«..1020..33343536..4050..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick